David Weidman, MD
Neurology · Phoenix, AZNPI 1467447656
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Eisai Inc. at 49.8% of the total. Reporting peaked in 2024 at $9,107 and has fallen 86.7% since, to $1,210 in 2025.
Across 62 payments — averaging $337.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$10K
- Eli Lilly$5K
- Biogen$4K
- Genentech USA, Inc.$291
- Roche Diagnostics Corporation$228
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$173
- plus $705 from 13 others
Across 153 payments — averaging $48,532 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4.1M
- Biogen$1.9M
- Eisai Inc.$1.1M
- Novartis$226K
- Genentech, Inc.$200
What the payments were for
- Consulting fees$8,15939%
- Speaking & faculty fees$7,78037%
- Travel & lodging$2,71813%
- Food & beverage$2,28211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 22 | $10,423 |
| Eli Lilly | 6 | $4,688 |
| Biogen | 6 | $4,432 |
| Genentech USA, Inc. | 4 | $291 |
| Roche Diagnostics Corporation | 2 | $228 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $173 |
| Novo Nordisk | 2 | $161 |
| Otsuka America Pharmaceutical, Inc. | 2 | $144 |
| Lilly USA, LLC | 1 | $90 |
| Medtronic | 1 | $59 |
| AstraZeneca | 3 | $57 |
| Argenx US, Inc. | 2 | $45 |
| Tonix Medicines, Inc. | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $19 |
| Novartis | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,939 in reported general payments places this provider in the 80th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 87 | $17,999 |
| BelsomraSuvorexant | 18 | $13,919 |
| Memantine Hcl | 74 | $5,131 |
| Galantamine ErGalantamine Hbr | 39 | $4,320 |
| Donepezil Hcl | 283 | $3,320 |
| RivastigmineRivastigmine Tartrate | 13 | $1,306 |
| Escitalopram Oxalate | 65 | $747 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 27 | $494 |
| Quetiapine Fumarate | 19 | $408 |
| Buspirone Hcl | 21 | $358 |
| Sertraline Hcl | 13 | $228 |
| Citalopram HbrCitalopram Hydrobromide | 54 | $202 |
| Methylphenidate Hcl | 15 | $194 |
| Trazodone Hcl | 29 | $155 |
Paid to pharmacies, not to this prescriber.
Other neurology in Phoenix
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
- Lori TravisPhoenix$406K
- Jeffrey GittPhoenix$275K
- Todd SchwedtPhoenix$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.